|
Sign In to gain access to subscriptions and/or personal tools.
|
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
Jay P Garg
Rush Presbyterian/St Luke’s Medical Center, Department of Preventive Medicine, Hypertension/Clinical Research Center, Chicago, IL, USA
George L Bakris
Rush Presbyterian/St Luke’s Medical Center, Department of Preventive Medicine, Hypertension/Clinical Research Center, Chicago, IL, USA, gbakrisKrush.edu
Based on the data from large single and multi-center clinical trials, including the Heart Outcomes Prevention Evaluation (HOPE) study, it is clear that the presence of microalbuminuria is a signal from the kidney that cardiovascular risk is increased and that vascular responses are altered. This is exemplified by studies that have demonstrated that the compensatory vaso-dilation seen following relief from prolonged ischemia or infusion of vasodilators such as nitroglycerin is blunted in people with microalbuminuria. Thus, the presence of between 30 and 299 mg/day of albumin in the urine is associated with abnormal vascular responsiveness, which may be the result of more advanced atherosclerosis and not necessarily related to the presence of hypertension or renal disease. Agents known to reduce the rise in microalbuminuria or actually reduce the level of microalbuminuria, such as ACE inhibitors, angiotensin receptor blockers, HMG-CoA reductase inhibitors, beta blockers, non-dihydropyridine calcium channel blockers and diuretics, have all been shown to reduce cardiovascular mortality and in some cases preserve renal function. This article will present an overview of the data that support the assertion that a reduction in the rise of microalbuminuria is a significant consideration in the selection of agents to treat a given risk factor (cholesterol or blood pressure) to a recommended target goal. Achieving such a goal with agents that also impact microalbuminuria will provide for a more complete cardiovascular risk reduction.
Key Words: ACE inhibitors • angiotensin II receptor blockers • cardiovascular disease • diabetes mellitus • hypertension • microalbuminuria • nephropathy
Vascular Medicine, Vol. 7, No. 1,
35-43 (2002)
DOI: 10.1191/1358863x02vm412ra
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. P. Stewart, P. Christian, K. J. Schulze, S. C. LeClerq, K. P. West Jr, and S. K. Khatry
Antenatal Micronutrient Supplementation Reduces Metabolic Syndrome in 6- to 8-Year-Old Children in Rural Nepal
J. Nutr.,
August 1, 2009;
139(8):
1575 - 1581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Renal Gene and Protein Expression Signatures for Prediction of Kidney Disease Progression
Am. J. Pathol.,
June 1, 2009;
174(6):
2073 - 2085.
|
|
|
|
|
|
|
American Diabetes Association
Standards of Medical Care in Diabetes--2009
Diabetes Care,
January 1, 2009;
32(Supplement_1):
S13 - S61.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Forman, N. D.L. Fisher, E. L. Schopick, and G. C. Curhan
Higher Levels of Albuminuria within the Normal Range Predict Incident Hypertension
J. Am. Soc. Nephrol.,
October 1, 2008;
19(10):
1983 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Diabetes Association
Standards of Medical Care in Diabetes--2008
Diabetes Care,
January 1, 2008;
31(Supplement_1):
S12 - S54.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Bakris
Protein Kinase C-{beta} Inhibition: A Promise Not Yet Fulfilled
Clin. J. Am. Soc. Nephrol.,
July 1, 2007;
2(4):
619 - 620.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Araki, M. Haneda, D. Koya, H. Hidaka, T. Sugimoto, M. Isono, K. Isshiki, M. Chin-Kanasaki, T. Uzu, and A. Kashiwagi
Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Diabetes,
June 1, 2007;
56(6):
1727 - 1730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Diabetes Association
Standards of Medical Care in Diabetes--2007
Diabetes Care,
January 1, 2007;
30(suppl_1):
S4 - S41.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Khosla and G. Bakris
Lessons Learned from Recent Hypertension Trials about Kidney Disease
Clin. J. Am. Soc. Nephrol.,
March 1, 2006;
1(2):
229 - 235.
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Diabetes Association
Standards of Medical Care in Diabetes-2006
Diabetes Care,
January 1, 2006;
29(suppl_1):
S4 - S42.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nakamura, K. Shikata, M. Hiramatsu, T. Nakatou, T. Kitamura, J. Wada, T. Itoshima, and H. Makino
Serum Interleukin-18 Levels Are Associated With Nephropathy and Atherosclerosis in Japanese Patients With Type 2 Diabetes
Diabetes Care,
December 1, 2005;
28(12):
2890 - 2895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, B. Waterhouse, M. A. Lukas, et al.
Differential Effects of {beta}-Blockers on Albuminuria in Patients With Type 2 Diabetes
Hypertension,
December 1, 2005;
46(6):
1309 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Araki, M. Haneda, T. Sugimoto, M. Isono, K. Isshiki, A. Kashiwagi, and D. Koya
Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes
Diabetes,
October 1, 2005;
54(10):
2983 - 2987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nathan, C. J. Pepine, and G. L. Bakris
Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients
Hypertension,
October 1, 2005;
46(4):
637 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lea, T. Greene, L. Hebert, M. Lipkowitz, S. Massry, J. Middleton, S. G. Rostand, E. Miller, W. Smith, G. L. Bakris, et al.
The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease: Results of the African American Study of Kidney Disease and Hypertension
Arch Intern Med,
April 25, 2005;
165(8):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Diabetes Association
Standards of Medical Care in Diabetes
Diabetes Care,
January 1, 2005;
28(suppl_1):
S4 - S36.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al.
Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial
JAMA,
November 10, 2004;
292(18):
2227 - 2236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Abbott, E. Basta, and G. L. Bakris
Blood Pressure Control and Nephroprotection in Diabetes
J. Clin. Pharmacol.,
April 1, 2004;
44(4):
431 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Chertow
A 43-Year-Old Woman With Chronic Renal Insufficiency
JAMA,
March 10, 2004;
291(10):
1252 - 1259.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al.
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Hypertension,
December 1, 2003;
42(6):
1206 - 1252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. I. Freedman, S. R. Beck, S. S. Rich, G. Heiss, C. E. Lewis, S. Turner, M. A. Province, K. L. Schwander, D. K. Arnett, and B. G. Mellen
A Genome-Wide Scan for Urinary Albumin Excretion in Hypertensive Families
Hypertension,
September 1, 2003;
42(3):
291 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rossing, P. K. Christensen, S. Andersen, P. Hovind, H. P. Hansen, and H.-H. Parving
Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure: A substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study
Diabetes Care,
March 1, 2003;
26(3):
569 - 574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
